Impact of mesenchymal stem cell therapy on cardiac function and outcomes in acute myocardial infarction: A meta-analysis of clinical studies
This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for...
Saved in:
| Published in | Cell transplantation Vol. 34; p. 9636897251359773 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Los Angeles, CA
SAGE Publications
01.08.2025
Sage Publications Ltd SAGE Publishing |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for AMI were identified from databases including Cochrane, Web of Science, PubMed, Embase, CNKI, and Wanfang, covering publications up to August 2024. Data analysis was conducted using Review Manager 5.4 software. MSC treatment significantly improved left ventricular ejection fraction (LVEF) compared to controls at follow-up intervals <6 months (MD = 3.42; P < 0.0001), 6 months (MD = 4.15; P = 0.006), and 12 months (MD = 2.77; P = 0.006). However, no significant effect on LVEF was observed after 12 months (MD = 3.50; P = 0.17). MSC therapy did not significantly affect left ventricular end-diastolic volume (LVEDV) at any interval. Left ventricular end-systolic volume (LVESV) significantly decreased only within the first 6 months (MD = −11.35; P = 0.11) but not at subsequent follow-ups. Wall motion score index (WMSI) significantly improved at <6 months (MD = −0.06; P < 0.0001), 6 months (MD = −0.04; P = 0.006), and >12 months (MD = −0.03; P = 0.02). However, the improvement at 12 months was borderline significant (MD = −0.06; P = 0.06). MSC therapy showed no significant reduction in MACE (odds ratio [OR] = 1.61; P = 0.10). Subgroup analyses indicated intracoronary MSC administration notably improved LVEF (MD = 4.27; P < 0.0001), while intravenous MSC administration showed no significant effect. Neither administration route significantly affected MACE outcomes. No publication bias was detected. In conclusion, MSC therapy significantly enhances LVEF and WMSI within the first 12 months post-AMI, with intracoronary administration showing greater efficacy than intravenous delivery. However, MSC treatment did not significantly reduce MACE incidence. Further rigorous clinical trials are needed to confirm these findings.
Graphical Abstract |
|---|---|
| AbstractList | This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for AMI were identified from databases including Cochrane, Web of Science, PubMed, Embase, CNKI, and Wanfang, covering publications up to August 2024. Data analysis was conducted using Review Manager 5.4 software. MSC treatment significantly improved left ventricular ejection fraction (LVEF) compared to controls at follow-up intervals <6 months (MD = 3.42; P < 0.0001), 6 months (MD = 4.15; P = 0.006), and 12 months (MD = 2.77; P = 0.006). However, no significant effect on LVEF was observed after 12 months (MD = 3.50; P = 0.17). MSC therapy did not significantly affect left ventricular end-diastolic volume (LVEDV) at any interval. Left ventricular end-systolic volume (LVESV) significantly decreased only within the first 6 months (MD = −11.35; P = 0.11) but not at subsequent follow-ups. Wall motion score index (WMSI) significantly improved at <6 months (MD = −0.06; P < 0.0001), 6 months (MD = −0.04; P = 0.006), and >12 months (MD = −0.03; P = 0.02). However, the improvement at 12 months was borderline significant (MD = −0.06; P = 0.06). MSC therapy showed no significant reduction in MACE (odds ratio [OR] = 1.61; P = 0.10). Subgroup analyses indicated intracoronary MSC administration notably improved LVEF (MD = 4.27; P < 0.0001), while intravenous MSC administration showed no significant effect. Neither administration route significantly affected MACE outcomes. No publication bias was detected. In conclusion, MSC therapy significantly enhances LVEF and WMSI within the first 12 months post-AMI, with intracoronary administration showing greater efficacy than intravenous delivery. However, MSC treatment did not significantly reduce MACE incidence. Further rigorous clinical trials are needed to confirm these findings. This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for AMI were identified from databases including Cochrane, Web of Science, PubMed, Embase, CNKI, and Wanfang, covering publications up to August 2024. Data analysis was conducted using Review Manager 5.4 software. MSC treatment significantly improved left ventricular ejection fraction (LVEF) compared to controls at follow-up intervals <6 months (MD = 3.42; P < 0.0001), 6 months (MD = 4.15; P = 0.006), and 12 months (MD = 2.77; P = 0.006). However, no significant effect on LVEF was observed after 12 months (MD = 3.50; P = 0.17). MSC therapy did not significantly affect left ventricular end-diastolic volume (LVEDV) at any interval. Left ventricular end-systolic volume (LVESV) significantly decreased only within the first 6 months (MD = −11.35; P = 0.11) but not at subsequent follow-ups. Wall motion score index (WMSI) significantly improved at <6 months (MD = −0.06; P < 0.0001), 6 months (MD = −0.04; P = 0.006), and >12 months (MD = −0.03; P = 0.02). However, the improvement at 12 months was borderline significant (MD = −0.06; P = 0.06). MSC therapy showed no significant reduction in MACE (odds ratio [OR] = 1.61; P = 0.10). Subgroup analyses indicated intracoronary MSC administration notably improved LVEF (MD = 4.27; P < 0.0001), while intravenous MSC administration showed no significant effect. Neither administration route significantly affected MACE outcomes. No publication bias was detected. In conclusion, MSC therapy significantly enhances LVEF and WMSI within the first 12 months post-AMI, with intracoronary administration showing greater efficacy than intravenous delivery. However, MSC treatment did not significantly reduce MACE incidence. Further rigorous clinical trials are needed to confirm these findings. Graphical Abstract This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for AMI were identified from databases including Cochrane, Web of Science, PubMed, Embase, CNKI, and Wanfang, covering publications up to August 2024. Data analysis was conducted using Review Manager 5.4 software. MSC treatment significantly improved left ventricular ejection fraction (LVEF) compared to controls at follow-up intervals <6 months (MD = 3.42; < 0.0001), 6 months (MD = 4.15; = 0.006), and 12 months (MD = 2.77; = 0.006). However, no significant effect on LVEF was observed after 12 months (MD = 3.50; = 0.17). MSC therapy did not significantly affect left ventricular end-diastolic volume (LVEDV) at any interval. Left ventricular end-systolic volume (LVESV) significantly decreased only within the first 6 months (MD = -11.35; = 0.11) but not at subsequent follow-ups. Wall motion score index (WMSI) significantly improved at <6 months (MD = -0.06; < 0.0001), 6 months (MD = -0.04; = 0.006), and >12 months (MD = -0.03; = 0.02). However, the improvement at 12 months was borderline significant (MD = -0.06; = 0.06). MSC therapy showed no significant reduction in MACE (odds ratio [OR] = 1.61; = 0.10). Subgroup analyses indicated intracoronary MSC administration notably improved LVEF (MD = 4.27; < 0.0001), while intravenous MSC administration showed no significant effect. Neither administration route significantly affected MACE outcomes. No publication bias was detected. In conclusion, MSC therapy significantly enhances LVEF and WMSI within the first 12 months post-AMI, with intracoronary administration showing greater efficacy than intravenous delivery. However, MSC treatment did not significantly reduce MACE incidence. Further rigorous clinical trials are needed to confirm these findings. This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for AMI were identified from databases including Cochrane, Web of Science, PubMed, Embase, CNKI, and Wanfang, covering publications up to August 2024. Data analysis was conducted using Review Manager 5.4 software. MSC treatment significantly improved left ventricular ejection fraction (LVEF) compared to controls at follow-up intervals <6 months (MD = 3.42; P < 0.0001), 6 months (MD = 4.15; P = 0.006), and 12 months (MD = 2.77; P = 0.006). However, no significant effect on LVEF was observed after 12 months (MD = 3.50; P = 0.17). MSC therapy did not significantly affect left ventricular end-diastolic volume (LVEDV) at any interval. Left ventricular end-systolic volume (LVESV) significantly decreased only within the first 6 months (MD = −11.35; P = 0.11) but not at subsequent follow-ups. Wall motion score index (WMSI) significantly improved at <6 months (MD = −0.06; P < 0.0001), 6 months (MD = −0.04; P = 0.006), and >12 months (MD = −0.03; P = 0.02). However, the improvement at 12 months was borderline significant (MD = −0.06; P = 0.06). MSC therapy showed no significant reduction in MACE (odds ratio [OR] = 1.61; P = 0.10). Subgroup analyses indicated intracoronary MSC administration notably improved LVEF (MD = 4.27; P < 0.0001), while intravenous MSC administration showed no significant effect. Neither administration route significantly affected MACE outcomes. No publication bias was detected. In conclusion, MSC therapy significantly enhances LVEF and WMSI within the first 12 months post-AMI, with intracoronary administration showing greater efficacy than intravenous delivery. However, MSC treatment did not significantly reduce MACE incidence. Further rigorous clinical trials are needed to confirm these findings. Graphical Abstract This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for AMI were identified from databases including Cochrane, Web of Science, PubMed, Embase, CNKI, and Wanfang, covering publications up to August 2024. Data analysis was conducted using Review Manager 5.4 software. MSC treatment significantly improved left ventricular ejection fraction (LVEF) compared to controls at follow-up intervals <6 months (MD = 3.42; P < 0.0001), 6 months (MD = 4.15; P = 0.006), and 12 months (MD = 2.77; P = 0.006). However, no significant effect on LVEF was observed after 12 months (MD = 3.50; P = 0.17). MSC therapy did not significantly affect left ventricular end-diastolic volume (LVEDV) at any interval. Left ventricular end-systolic volume (LVESV) significantly decreased only within the first 6 months (MD = -11.35; P = 0.11) but not at subsequent follow-ups. Wall motion score index (WMSI) significantly improved at <6 months (MD = -0.06; P < 0.0001), 6 months (MD = -0.04; P = 0.006), and >12 months (MD = -0.03; P = 0.02). However, the improvement at 12 months was borderline significant (MD = -0.06; P = 0.06). MSC therapy showed no significant reduction in MACE (odds ratio [OR] = 1.61; P = 0.10). Subgroup analyses indicated intracoronary MSC administration notably improved LVEF (MD = 4.27; P < 0.0001), while intravenous MSC administration showed no significant effect. Neither administration route significantly affected MACE outcomes. No publication bias was detected. In conclusion, MSC therapy significantly enhances LVEF and WMSI within the first 12 months post-AMI, with intracoronary administration showing greater efficacy than intravenous delivery. However, MSC treatment did not significantly reduce MACE incidence. Further rigorous clinical trials are needed to confirm these findings.This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI) at various follow-up intervals. Clinical studies comparing MSC therapy with control treatments for AMI were identified from databases including Cochrane, Web of Science, PubMed, Embase, CNKI, and Wanfang, covering publications up to August 2024. Data analysis was conducted using Review Manager 5.4 software. MSC treatment significantly improved left ventricular ejection fraction (LVEF) compared to controls at follow-up intervals <6 months (MD = 3.42; P < 0.0001), 6 months (MD = 4.15; P = 0.006), and 12 months (MD = 2.77; P = 0.006). However, no significant effect on LVEF was observed after 12 months (MD = 3.50; P = 0.17). MSC therapy did not significantly affect left ventricular end-diastolic volume (LVEDV) at any interval. Left ventricular end-systolic volume (LVESV) significantly decreased only within the first 6 months (MD = -11.35; P = 0.11) but not at subsequent follow-ups. Wall motion score index (WMSI) significantly improved at <6 months (MD = -0.06; P < 0.0001), 6 months (MD = -0.04; P = 0.006), and >12 months (MD = -0.03; P = 0.02). However, the improvement at 12 months was borderline significant (MD = -0.06; P = 0.06). MSC therapy showed no significant reduction in MACE (odds ratio [OR] = 1.61; P = 0.10). Subgroup analyses indicated intracoronary MSC administration notably improved LVEF (MD = 4.27; P < 0.0001), while intravenous MSC administration showed no significant effect. Neither administration route significantly affected MACE outcomes. No publication bias was detected. In conclusion, MSC therapy significantly enhances LVEF and WMSI within the first 12 months post-AMI, with intracoronary administration showing greater efficacy than intravenous delivery. However, MSC treatment did not significantly reduce MACE incidence. Further rigorous clinical trials are needed to confirm these findings. |
| Author | Tian, Qingqing Deng, Yan Zhao, Mei Tang, Tao Xue, Yanpeng |
| AuthorAffiliation | 3 Department of Obstetrics and Gynecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China 1 Department of Pharmacy, Sanya Central Hospital (The Third People’s Hospital of Hainan Province), Sanya, China 2 Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China |
| AuthorAffiliation_xml | – name: 1 Department of Pharmacy, Sanya Central Hospital (The Third People’s Hospital of Hainan Province), Sanya, China – name: 2 Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China – name: 3 Department of Obstetrics and Gynecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China |
| Author_xml | – sequence: 1 givenname: Mei orcidid: 0000-0002-2653-3142 surname: Zhao fullname: Zhao, Mei email: hrb_xiaozhaomei@163.com – sequence: 2 givenname: Yanpeng surname: Xue fullname: Xue, Yanpeng – sequence: 3 givenname: Qingqing surname: Tian fullname: Tian, Qingqing – sequence: 4 givenname: Yan surname: Deng fullname: Deng, Yan – sequence: 5 givenname: Tao orcidid: 0000-0003-0653-7987 surname: Tang fullname: Tang, Tao |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40755274$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kktv1DAQxy1URLeFD8AFWeLCJcWPOE64oKrisVIlLnC2Zp3JrleJvdhJpf0OfGicTSkUxMn2zG_-8_BckDMfPBLykrMrzrV-y5pKVnWjheJSNVrLJ2TFlVKFrBtxRlazv5iBc3KR0p4xpqVQz8h5ybRSQpcr8mM9HMCONHR0wITe7o4D9DSNOFCLfU_HHUY4HGnw1EJsHVjaTd6OLhvAtzRMow05lLr8ttOIdDiGheyzrYN4Yt_R65xghAI89Mfk0pzR9s47e0o3tQ7Tc_K0gz7hi_vzknz7-OHrzefi9sun9c31bWFLJmRhmUQBqBvBBECrgUHuXrTQgbacdyi7msu2FLquuhIrzHeFoss9V8BRy0uyXnTbAHtziG6AeDQBnDkZQtwaiKOzPZrGsg3wPFTJ6rJWWDcoNhxK1aiWoxVZ6_2idZg2A7YW_RihfyT62OPdzmzDneFCCiHLJiu8uVeI4fuEaTSDS_PswWOYkpFCVkKwUtUZff0Xug9TzBM9UarJZZVzSa_-LOmhll-_ngG-ADaGlCJ2DwhnZt4s889m5ZirJSbBFn-n_X_AT3hOzrg |
| Cites_doi | 10.1016/j.jjcc.2021.10.030 10.1056/NEJMra1606915 10.3390/cells9051145 10.1093/stcltm/szac004 10.1056/NEJMra022700 10.1002/sctm.17-0129 10.1016/j.molmed.2020.01.003 10.1007/s12265-013-9507-7 10.1186/s13287-020-02096-6 10.1016/j.amjmed.2022.08.017 10.1093/eurheartj/ehp536 10.1161/CIR.0000000000000985 10.14797/mdcj-16-1-16 10.1177/153537020623100105 10.3727/096368915X686841 10.1155/2020/1215802 10.1093/eurheartj/ehn220 10.1097/JIM.0000000000000232 10.1186/s12916-015-0399-z 10.1007/s10529-014-1589-z 10.1016/j.trsl.2009.06.009 10.1016/j.jacc.2009.06.055 10.3346/jkms.2014.29.1.23 10.1016/j.jcyt.2014.10.009 10.1016/j.amjcard.2004.03.034 10.1038/nri2395 10.1016/j.pharmthera.2014.02.013 10.1186/s13287-023-03495-1 10.1016/j.ijcard.2013.04.112 10.1007/s10557-018-6804-z 10.1002/jcb.20949 10.2217/fca-2017-0072 10.1038/nature13839 10.1016/j.suc.2022.01.007 10.1161/JAHA.123.029971 10.1080/14712598.2023.2245329 10.2174/1574888X18666230823091017 10.1016/j.ijcard.2007.04.098 10.1016/j.biopha.2023.114817 10.1016/j.jacc.2011.09.065 10.1089/rej.2009.0986 10.1038/s41392-022-01134-4 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 The Author(s) 2025 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| Copyright_xml | – notice: The Author(s) 2025 – notice: The Author(s) 2025 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| DBID | AFRWT AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 8FD FR3 H94 K9. P64 RC3 7X8 5PM DOA |
| DOI | 10.1177/09636897251359773 |
| DatabaseName | Sage Journals GOLD Open Access 2024 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | Genetics Abstracts CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: AFRWT name: Sage Journals GOLD Open Access 2024 url: http://journals.sagepub.com/ sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering Anatomy & Physiology Biology |
| EISSN | 1555-3892 |
| ExternalDocumentID | oai_doaj_org_article_9c0ba1155308485e89e2b1a4595d1ec2 PMC12322349 40755274 10_1177_09636897251359773 10.1177_09636897251359773 |
| Genre | Meta-Analysis Journal Article |
| GroupedDBID | --- --K 0R~ 0VX 1B1 29B 4.4 53G 54M 5GY 7X7 8FI 8FJ AAEDT AAEJI AAGGD AALRI AAPEO AAQGT AAQXH AAQXK AASGM AAXUO ABDWY ABJIS ABQKF ABQXT ABUWG ABVFX ABWVN ABYTW ACARO ACFMA ACGBL ACHEB ACLHI ACROE ACRPL ACVFH ADBBV ADCNI ADEIA ADMUD ADNMO ADOGD ADTBJ ADUKL AENEX AEUPX AEWDL AFCOW AFDWT AFKRA AFKRG AFPUW AFRWT AFYCX AGQPQ AJEFB AJMMQ AJUZI ALMA_UNASSIGNED_HOLDINGS AOIJS APTNG AUTPY AYAKG BAWUL BCNDV BDDNI BENPR BPHCQ BSEHC BVXVI CBRKF CCPQU CORYS CQQTX CS3 DC. DU5 EBS EJD EMOBN F5P FDB FEDTE FGOYB FYUFA GROUPED_DOAJ H13 HMCUK HVGLF HYE HZ~ IHE J8X K.F M41 NQ- OK1 P2P PHGZM PHGZT PIMPY PQQKQ Q1R R2- R9- ROL RPM RPZ SAUOL SCDPB SCNPE SFC UHS UKHRP AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7T5 8FD FR3 H94 K9. P64 RC3 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c4023-c03e2ae79202aad7a0a5972dafa7c11fe3f813d42786f4e6e3d45e2f7556a1e73 |
| IEDL.DBID | AFRWT |
| ISSN | 0963-6897 1555-3892 |
| IngestDate | Wed Aug 27 01:32:00 EDT 2025 Thu Aug 21 18:29:59 EDT 2025 Mon Aug 04 16:31:02 EDT 2025 Wed Aug 13 11:41:02 EDT 2025 Sun Aug 10 01:32:09 EDT 2025 Thu Aug 14 00:12:06 EDT 2025 Sun Aug 17 05:41:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | mesenchymal stem cell major adverse cardiac eventsIntroduction left ventricular end-diastolic volume left ventricular end-systolic volume acute myocardial infarction left ventricular ejection fraction |
| Language | English |
| License | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4023-c03e2ae79202aad7a0a5972dafa7c11fe3f813d42786f4e6e3d45e2f7556a1e73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0003-0653-7987 0000-0002-2653-3142 |
| OpenAccessLink | https://journals.sagepub.com/doi/full/10.1177/09636897251359773?utm_source=summon&utm_medium=discovery-provider |
| PMID | 40755274 |
| PQID | 3235945942 |
| PQPubID | 4450831 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9c0ba1155308485e89e2b1a4595d1ec2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12322349 proquest_miscellaneous_3236220458 proquest_journals_3235945942 pubmed_primary_40755274 crossref_primary_10_1177_09636897251359773 sage_journals_10_1177_09636897251359773 |
| PublicationCentury | 2000 |
| PublicationDate | 20250800 |
| PublicationDateYYYYMMDD | 2025-08-01 |
| PublicationDate_xml | – month: 8 year: 2025 text: 20250800 |
| PublicationDecade | 2020 |
| PublicationPlace | Los Angeles, CA |
| PublicationPlace_xml | – name: Los Angeles, CA – name: United States – name: Thousand Oaks – name: Sage CA: Los Angeles, CA |
| PublicationTitle | Cell transplantation |
| PublicationTitleAlternate | Cell Transplant |
| PublicationYear | 2025 |
| Publisher | SAGE Publications Sage Publications Ltd SAGE Publishing |
| Publisher_xml | – name: SAGE Publications – name: Sage Publications Ltd – name: SAGE Publishing |
| References | Berezin, Berezin 2020; 2020 Ding, Chang, Shyu, Lin 2015; 24 Bajaj, Sethi, Rathor, Suppogu, Sethi 2015; 63 Chen, Fang, Ye, Liu, Qian, Shan, Zhang, Chunhua, Liao, Lin, Sun 2004; 94 Hare, Traverse, Henry, Dib, Strumpf, Schulman, Gerstenblith, DeMaria, Denktas, Gammon, Hermiller 2009; 54 Kim, Cho, Lee, Lee, Kim, Kim, Lee, Kang, Lee, Ahn, Jeong 2018; 32 Matsushita 2020; 26 Hoang, Pham, Bach, Ngo, Nguyen, Phan, Nguyen, Le, Hoang, Forsyth, Heke 2022; 7 George 2010; 155 Mishra, Shih, Parveen, Lenzen, Ito, Chan, Ke 2020; 9 Henning 2018; 14 Chullikana, Majumdar, Gottipamula, Krishnamurthy, Kumar, Prakash, Gupta 2015; 17 Mathur, Sim, Choudry, Veerapen, Colicchia, Turlejski, Hussain, Hamshere, Locca, Rakhit, Crake 2022; 9 Zhang, Ge, Sun, Xu, Qian, Lin, Zhao, Hu, Li, Wang, Zou 2006; 99 Bronckaers, Hilkens, Martens, Gervois, Ratajczak, Struys, Lambrichts 2014; 143 Damluji, van Diepen, Katz, Menon, Tamis-Holland, Bakitas, Cohen, Balsam, Chikwe 2021; 144 Minguell, Erices 2006; 231 Murphy, Goldberg 2022; 135 Gao, Pei, Ding, Chen, Zhang, Chen, Wang, Wang, Zhu, Li, Liu 2013; 168 Grajek, Popiel, Gil, Bręborowicz, Lesiak, Czepczyński, Sawiński, Straburzyńska-Migaj, Araszkiewicz, Czyż, Kozłowska-Skrzypczak 2009; 31 Zimetbaum, Josephson 2003; 348 Martin-Rendon, Brunskill, Hyde, Stanworth, Mathur, Watt 2008; 29 Weng, Wang, Ouchi, Liu, Qiao, Wu, Zhao, Li, Li 2022; 11 Meluzín, Janousek, Mayer, Groch, Hornácek, Hlinomaz, Kala, Panovský, Prásek, Kamínek, Stanícek 2008; 128 Samsonraj, Raghunath, Nurcombe, Hui, van Wijnen, Cool 2017; 6 Krittanawong, Khawaja, Tamis-Holland, Girotra, Rao 2023; 12 Lee, Lee, Youn, Ahn, Kim, Yoo, Yoon, Kwon, Hong, Lee, Kwan 2014; 29 Zhang, Yu, Zhang, Li, Wang, Cai, Chen, Yang, Liu 2021; 12 Fan, Chen, Liu, Du, Jiang, Tian, Sun, Li, Tian 2010; 13 Houtgraaf, den Dekker, van Dalen, Springeling, de Jong, van Geuns, Geleijnse, Fernandez-Aviles, Zijlsta, Serruys, Ducker 2012; 59 Clavellina, Balkan, Hare 2023; 23 Pan, Wu, Jiang, Liu 2023; 163 Kinkaid, Huang, Li, Weisel 2010; 25 Anderson, Morrow 2017; 376 Wang, Xi, Wang 2014; 36 Uccelli, Moretta, Pistoia 2008; 8 Rodrigo, van Ramshorst, Hoogslag, Boden, Velders, Cannegieter, Roelofs, Al Younis, Dibbets-Schneider, Fibbe, Zwaginga 2013; 6 Duggan, Peters, Trachiotis, Antevil 2022; 102 Kapur, Thayer, Zweck 2020; 16 Yamada, Minatoguchi, Kanamori, Mikami, Okura, Dezawa, Minatoguchi 2022; 80 Yang, Ma, Ma, Bai 2024; 19 Gao, Chen, Zhang, Yang, Liu, Wang, Yan, Wang, Zhu, Li, Wang 2015; 13 Ubil, Duan, Pillai, Rosa-Garrido, Wu, Bargiacchi, Lu, Stanbouly, Huang, Rojas, Vondriska 2014; 514 Attar, Farjoud Kouhanjani, Hessami, Vosough, Kojuri, Ramzi, Hosseini, Faghih, Monabati 2023; 14 e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 Kinkaid HY (e_1_3_3_41_2) 2010; 25 e_1_3_3_40_2 Mathur A (e_1_3_3_33_2) 2022; 9 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 |
| References_xml | – volume: 19 issue: 7 year: 2024 article-title: Research progress on cardiac tissue construction of mesenchymal stem cells for myocardial infarction publication-title: Curr Stem Cell Res Ther – volume: 13 start-page: 162 year: 2015 article-title: Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial publication-title: BMC Med – volume: 29 start-page: 23 issue: 1 year: 2014 end-page: 31 article-title: A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction publication-title: J Korean Med Sci – volume: 2020 start-page: 1215802 year: 2020 article-title: Adverse cardiac remodelling after acute myocardial infarction: old and new biomarkers publication-title: Dis Markers – volume: 9 start-page: 1145 issue: 5 year: 2020 article-title: Identifying the therapeutic significance of mesenchymal stem cells publication-title: Cells – volume: 94 start-page: 92 issue: 1 year: 2004 end-page: 95 article-title: Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction publication-title: Am J Cardiol – volume: 9 issue: 2 year: 2022 article-title: Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial publication-title: ESC Heart Fail – volume: 143 issue: 2 year: 2014 article-title: Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis publication-title: Pharmacol Ther – volume: 63 issue: 7 year: 2015 article-title: Acute complications of myocardial infarction in the current era: diagnosis and management publication-title: J Investig Med – volume: 14 issue: 2 year: 2018 article-title: Current status of stem cells in cardiac repair publication-title: Future Cardiol – volume: 376 issue: 21 year: 2017 article-title: Acute myocardial infarction publication-title: N Engl J Med – volume: 17 issue: 3 year: 2015 article-title: Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction publication-title: Cytotherapy – volume: 13 issue: 4 year: 2010 article-title: The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction publication-title: Rejuvenation Res – volume: 24 issue: 3 year: 2015 article-title: Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy publication-title: Cell Transplant – volume: 14 start-page: 264 issue: 1 year: 2023 article-title: Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial publication-title: Stem Cell Research & Therapy – volume: 128 issue: 2 year: 2008 article-title: Three-, 6-, and 12-month results of autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction publication-title: Int J Cardiol – volume: 25 issue: 3 year: 2010 article-title: What’s new in cardiac cell therapy? allogeneic bone marrow stromal cells as “universal donor cells publication-title: ” J Card Surg – volume: 102 start-page: 499 issue: 3 year: 2022 end-page: 516 article-title: Epidemiology of coronary artery disease publication-title: Surg Clin North Am – volume: 514 issue: 7524 year: 2014 article-title: Mesenchymal–endothelial transition contributes to cardiac neovascularization publication-title: Nature – volume: 155 start-page: 10 issue: 1 year: 2010 end-page: 19 article-title: Stem cell therapy in acute myocardial infarction: a review of clinical trials publication-title: Transl Res – volume: 6 issue: 12 year: 2017 article-title: Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine publication-title: Stem Cells Transl Med – volume: 59 issue: 5 year: 2012 article-title: First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction publication-title: J Am Coll Cardiol – volume: 29 issue: 15 year: 2008 article-title: Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review publication-title: Eur Heart J – volume: 8 issue: 9 year: 2008 article-title: Mesenchymal stem cells in health and disease publication-title: Nat Rev Immunol – volume: 99 issue: 4 year: 2006 article-title: Comparison of various kinds of bone marrow stem cells for the repair of infarcted myocardium: single clonally purified non-hematopoietic mesenchymal stem cells serve as a superior source publication-title: J Cell Biochem – volume: 348 issue: 10 year: 2003 article-title: Use of the electrocardiogram in acute myocardial infarction publication-title: N Engl J Med – volume: 144 issue: 2 year: 2021 article-title: Mechanical complications of acute myocardial infarction: a scientific statement from the American Heart Association publication-title: Circulation – volume: 168 issue: 4 year: 2013 article-title: A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction publication-title: Int J Cardiol – volume: 16 start-page: 16 issue: 1 year: 2020 end-page: 21 article-title: Cardiogenic shock in the setting of acute myocardial infarction publication-title: Methodist Debakey Cardiovasc J – volume: 12 start-page: 33 issue: 1 year: 2021 article-title: Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction: single-blind, multicenter, randomized controlled trial publication-title: Stem Cell Res Ther – volume: 12 issue: 18 year: 2023 article-title: Acute myocardial infarction: etiologies and mimickers in young patients publication-title: J Am Heart Assoc – volume: 231 start-page: 39 issue: 1 year: 2006 end-page: 49 article-title: Mesenchymal stem cells and the treatment of cardiac disease publication-title: Exp Biol Med (Maywood) – volume: 163 start-page: 114817 year: 2023 article-title: Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular diseases: from mechanisms to therapy publication-title: Biomed Pharmacother – volume: 7 start-page: 272 issue: 1 year: 2022 article-title: Stem cell-based therapy for human diseases publication-title: Signal Transduct Target Ther – volume: 54 issue: 24 year: 2009 article-title: A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction publication-title: J Am Coll Cardiol – volume: 80 start-page: 80 issue: 1 year: 2022 end-page: 87 article-title: Stem cell therapy for acute myocardial infarction–focusing on the comparison between Muse cells and mesenchymal stem cells publication-title: J Cardiol – volume: 31 start-page: 691 issue: 6 year: 2009 end-page: 702 article-title: Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation publication-title: Eur Heart J – volume: 36 issue: 11 year: 2014 article-title: The beneficial effects of intracoronary autologous bone marrow stem cell transfer as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction publication-title: Biotechnol Lett – volume: 26 issue: 4 year: 2020 article-title: Heart failure and adipose mesenchymal stem cells publication-title: Trends Mol Med – volume: 6 issue: 5 year: 2013 article-title: Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up publication-title: J Cardiovasc Transl Res – volume: 23 issue: 10 year: 2023 article-title: Stem cell therapy for acute myocardial infarction: mesenchymal stem cells and induced pluripotent stem cells publication-title: Expert Opin Biol Ther – volume: 11 issue: 4 year: 2022 article-title: Mesenchymal stem/stromal cell senescence: hallmarks, mechanisms, and combating strategies publication-title: Stem Cells Transl Med – volume: 32 issue: 4 year: 2018 article-title: Improvement in left ventricular function with intracoronary mesenchymal stem cell therapy in a patient with anterior wall ST-segment elevation myocardial infarction publication-title: Cardiovasc Drugs Ther – volume: 135 issue: 12 year: 2022 article-title: Mechanical complications of myocardial infarction publication-title: Am J Med – ident: e_1_3_3_20_2 doi: 10.1016/j.jjcc.2021.10.030 – ident: e_1_3_3_4_2 doi: 10.1056/NEJMra1606915 – ident: e_1_3_3_12_2 doi: 10.3390/cells9051145 – ident: e_1_3_3_16_2 doi: 10.1093/stcltm/szac004 – ident: e_1_3_3_9_2 doi: 10.1056/NEJMra022700 – ident: e_1_3_3_13_2 doi: 10.1002/sctm.17-0129 – ident: e_1_3_3_18_2 doi: 10.1016/j.molmed.2020.01.003 – ident: e_1_3_3_34_2 doi: 10.1007/s12265-013-9507-7 – ident: e_1_3_3_36_2 doi: 10.1186/s13287-020-02096-6 – ident: e_1_3_3_7_2 doi: 10.1016/j.amjmed.2022.08.017 – ident: e_1_3_3_28_2 doi: 10.1093/eurheartj/ehp536 – ident: e_1_3_3_3_2 doi: 10.1161/CIR.0000000000000985 – ident: e_1_3_3_6_2 doi: 10.14797/mdcj-16-1-16 – ident: e_1_3_3_39_2 doi: 10.1177/153537020623100105 – ident: e_1_3_3_14_2 doi: 10.3727/096368915X686841 – ident: e_1_3_3_10_2 doi: 10.1155/2020/1215802 – ident: e_1_3_3_45_2 doi: 10.1093/eurheartj/ehn220 – ident: e_1_3_3_8_2 doi: 10.1097/JIM.0000000000000232 – ident: e_1_3_3_27_2 doi: 10.1186/s12916-015-0399-z – ident: e_1_3_3_35_2 doi: 10.1007/s10529-014-1589-z – ident: e_1_3_3_37_2 doi: 10.1016/j.trsl.2009.06.009 – ident: e_1_3_3_29_2 doi: 10.1016/j.jacc.2009.06.055 – ident: e_1_3_3_32_2 doi: 10.3346/jkms.2014.29.1.23 – ident: e_1_3_3_25_2 doi: 10.1016/j.jcyt.2014.10.009 – ident: e_1_3_3_24_2 doi: 10.1016/j.amjcard.2004.03.034 – volume: 25 issue: 3 year: 2010 ident: e_1_3_3_41_2 article-title: What’s new in cardiac cell therapy? allogeneic bone marrow stromal cells as “universal donor cells publication-title: ” J Card Surg – ident: e_1_3_3_11_2 doi: 10.1038/nri2395 – ident: e_1_3_3_40_2 doi: 10.1016/j.pharmthera.2014.02.013 – ident: e_1_3_3_23_2 doi: 10.1186/s13287-023-03495-1 – ident: e_1_3_3_26_2 doi: 10.1016/j.ijcard.2013.04.112 – ident: e_1_3_3_31_2 doi: 10.1007/s10557-018-6804-z – ident: e_1_3_3_38_2 doi: 10.1002/jcb.20949 – ident: e_1_3_3_21_2 doi: 10.2217/fca-2017-0072 – ident: e_1_3_3_42_2 doi: 10.1038/nature13839 – ident: e_1_3_3_2_2 doi: 10.1016/j.suc.2022.01.007 – ident: e_1_3_3_5_2 doi: 10.1161/JAHA.123.029971 – ident: e_1_3_3_19_2 doi: 10.1080/14712598.2023.2245329 – ident: e_1_3_3_22_2 doi: 10.2174/1574888X18666230823091017 – ident: e_1_3_3_44_2 doi: 10.1016/j.ijcard.2007.04.098 – volume: 9 issue: 2 year: 2022 ident: e_1_3_3_33_2 article-title: Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial publication-title: ESC Heart Fail – ident: e_1_3_3_15_2 doi: 10.1016/j.biopha.2023.114817 – ident: e_1_3_3_30_2 doi: 10.1016/j.jacc.2011.09.065 – ident: e_1_3_3_43_2 doi: 10.1089/rej.2009.0986 – ident: e_1_3_3_17_2 doi: 10.1038/s41392-022-01134-4 |
| SSID | ssj0007325 |
| Score | 2.4382985 |
| SecondaryResourceType | review_article |
| Snippet | This meta-analysis evaluated the efficacy of mesenchymal stem cell (MSC) treatment on cardiovascular function and major adverse cardiac events (MACE) in... |
| SourceID | doaj pubmedcentral proquest pubmed crossref sage |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 9636897251359773 |
| SubjectTerms | Cell therapy Clinical trials Heart Heart attacks Humans Intravenous administration Mesenchymal Stem Cell Transplantation - methods Mesenchymal stem cells Mesenchymal Stem Cells - cytology Meta-analysis Myocardial infarction Myocardial Infarction - physiopathology Myocardial Infarction - therapy Original Stem cells Stroke Volume Treatment Outcome Ventricle Ventricular Function, Left - physiology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kQdCD6K6P6CotiIIQTD_SnXibFZdV0JMLewuVToVdcJLFyRzmP_ijreok44wPvHhL0kW6qfo61dWp_kqIF611CjOAtNE-pBZskULmfZqjQ2vL1njkfchPn93Zuf14kV_slPrinLCRHnhU3JsyZDWoWN2msEWORYm6VmDzMm8Uhvj1JZ83B1PTN9gbnU__MCO9EsHMFaUnZ26YcM3seaFI1v-nFebviZI72V7RAZ3eFXemlaNcjCO-J25gdyiOFh1FzcuNfCljLmfcJD8UN0_mq9s7hINH4vuHeChS9q1c8rGjcLlZ0juZzFnyFr4cj2NtZN_JELETJHs-tp6ErpH9eiCI4kpe0X1YDyiXm36U_ErPWpo2LPtWLqiDAVKYOE-4x_kQplyNuYv3xfnp-y_vztKpHkMaKMo0acgMakBf6kwDNB4yIGXqBlrwQakWTVso03DxDtdaMjZd56hbn-cOFHrzQBx0fYePhNS2Nk6B1pGysDC1RmeBQssanPe-TMTr2T7V9Ui7UamZmfxXYybihC24FWTG7PiAcFRNOKr-haNEHM_2r6ZpvKqMph5IxFLz820zTUA2CXTYr6OM00zqXyTi4QiX7UgoWmaGO5uIYg9Ie0Pdb-muLiPJNy91tbGkiVeMuZ9j-qsaHv8PNTwRtzRXOI4pjsfiYPi2xqe07BrqZ3GG_QANNibc priority: 102 providerName: Directory of Open Access Journals |
| Title | Impact of mesenchymal stem cell therapy on cardiac function and outcomes in acute myocardial infarction: A meta-analysis of clinical studies |
| URI | https://journals.sagepub.com/doi/full/10.1177/09636897251359773 https://www.ncbi.nlm.nih.gov/pubmed/40755274 https://www.proquest.com/docview/3235945942 https://www.proquest.com/docview/3236220458 https://pubmed.ncbi.nlm.nih.gov/PMC12322349 https://doaj.org/article/9c0ba1155308485e89e2b1a4595d1ec2 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEF_6gaAPoq3WaD1WEAVhbbK72U18kTvpUQWLlBbvLWw2G1swifSSh_sf_KOd2SRnTyv4dLndIbPMR_Zr5jeEvCylilxoDCu4tkwamTATas1ip5yUaSm0w3PIz6fq5EJ-WsSLLdKMuTCDBJdvMawKRuQ_1ujdeBp9NFwyHsG6W6gk1TA5CwRQE--7tsr64-6xqga24P10V-HVtsWAyBUb09u2yS7XKgZP3p3Oz76erz_eWvg6rciAIYfhIvRWphtTmUf8v22Z-ne05Y2QMT-LzR-Q-8Pyk057e3lItly9R_anNWy9qxV9RX1AqD9p3yN3ZuPTvRuohfvk50efWUmbklaYu2QvVxW8ExGhKd4D0D6na0WbmlpvgJbi9IkmQE1d0KZrQd5uSa_gv-1aR6tV01N-h7YSfA9p39EpMGgNMwNwCnIcMznpsg-AfEQu5sfnH07YUNSBWdiqCmZD4bhxOuUhN6bQJjQgTF6Y0mgbRaUTZRKJAiuAqFKCxcBz7Hip41iZyGnxmOzUTe2eEMplLlRkOPe4h4nIuVPSwP40N0prnQbkzaif7EeP3ZFFI7z5n8oMyAw1uCZE2G3f0Fx_ywYvzlIb5ibypZYSmcQuSR3PIyPjNC4iZ3lADkf9Z6MlZ4IDByCR0P1i3Q1ejCoxtWs6T6M4VgZIAnLQm8t6JLDlRpg8GZBkw5A2hrrZU19deqRwXC9zIUESr9Hmfo_pn2J4-t-Uz8hdjrWQfTDkIdlprzv3HBZobT4h23qhJ4Nrwe_s-PTL2cQfd_wCzYE4OQ |
| linkProvider | SAGE Publications |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZgKwQcELRAFwoYCYGElCp-JE64bRGrLbQ9oK3oLZo4Dq3UTVA3e9j_wI9mxnnQhSJxc-JJbM0jYzsz3zD2ptSxcCFAUEhjAw06CSA0Johc7LROS2UcnUMen8SzU_35LDrroiopF6bj4HKfwqpwRv5jPVg3ISWhxsRJatAvK8JOU7fZliavNWJbk-nXb_PhO2yUL7lKDwT0RPdP88aXbHglD95_04rz78DJa9Ff3iFNH7IH3UqST1rRP2K3XLXNdiYV7qIXa_6W-9hOf2i-ze4c9K371wAId9jPQ58kyeuSLygNyZ6vF_hOAnfmdKTP2_SsNa8rbr0uWU6ekKTJoSp4vWqQdW7JL_DarhrHF-u6pbzEeyWaEdF-4BMcoIEAOgwUGrFPyuTLNpbxMTudfpp_nAVdfYbA4q5TBTZUToIzqQwlQGEgBGSmLKAEY4UonSoToQoq5hGXGoWP7cjJ0kRRDMIZ9YSNqrpyu4xLnatYgJQewjBRuXSxBtxq5hAbY9Ixe9_LJ_vRwnBkokcq_1OYY3ZAEhwICUHb36ivvmedQWapDXMQvmpSopPIJamTuQAdpVEhnJVjttfLP-uVMlMSR0ASjd2vh240SBIJVK5eeZpYEsh_MmZPW3UZZoK7Z0K802OWbCjSxlQ3e6qLcw_6TUtfqTRy4h3p3O85_ZMNz_6b8hW7O5sfH2VHhydfnrN7kkoc-xjHPTZqrlbuBa67mvxlZ2C_AH5CIiw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZgKxAcELQ8FgoYCYGEFJrYjp1w2wKrlkeFUCt6iyaOTSuxSdXNHvY_8KOZcZKlC0XilsST2JpHPLZnvmHsuVc6cTFAVAljIwUqiyA2JkqddkrlXhpH-5CfD_TekfpwnB73G26UC9NzcP6awqpwROFnTdZ9Vvmd_oxxB91uqbPc4NwsCT9NXmUbSuHcOGIbk-nXb4erf7GRoewqvRDRG_255qUfWZuZAoD_ZV7n38GTFyLAwqQ0vc1u9d4kn3Tiv8OuuHqTbU1qXEnPlvwFD_GdYeN8k13bHa5uXgAh3GI_90OiJG88n1Eqkj1ZzvCbBPDMaVufdylaS97U3AZ9spxmQ5Ioh7rizaJF9rk5P8V7u2gdny2bjvIHPvNoSkT7hk-wgxYi6HFQqMchMZPPu3jGu-xo-v7w7V7U12iILK48ZWRj6QQ4k4tYAFQGYkBmigo8GJsk3kmfJbKigh7aK1QAvE6d8CZNNSTOyHtsVDe1e8C4UKXUCQgRYAwzWQqnFeByswRtjMnH7NUgn-Ksg-IokgGt_E9hjtkuSXBFSCja4UFz_r3ojbLIbVxCEionZSpLXZY7USag0jytEmfFmG0P8i8GxSykwB6QRGHzs1UzGiWJBGrXLAKNFgT0n43Z_U5dViPBFTSh3qkxy9YUaW2o6y316UkA_ib3V0iFnHhJOvd7TP9kw8P_pnzKrn95Ny0-7R98fMRuCKpyHMIct9moPV-4x-h6teWT3r5-AcaEIzw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+mesenchymal+stem+cell+therapy+on+cardiac+function+and+outcomes+in+acute+myocardial+infarction%3A+A+meta-analysis+of+clinical+studies&rft.jtitle=Cell+transplantation&rft.au=Zhao%2C+Mei&rft.au=Xue+Yanpeng&rft.au=Tian+Qingqing&rft.au=Deng%2C+Yan&rft.date=2025-08-01&rft.pub=Sage+Publications+Ltd&rft.issn=0963-6897&rft.eissn=1555-3892&rft.volume=34&rft_id=info:doi/10.1177%2F09636897251359773&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0963-6897&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0963-6897&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0963-6897&client=summon |